|
|
| |
 |
 |
Francis Berenbaum,
M.D., Ph.D
|
| |
Dr. Berenbaum is the
leader of "Ageing, Inflammation and Osteoarthritis" group at Pierre
& Marie Curie University and is the Director of the Department
of Rheumatology at AP-HP Saint-Antoine Hospital in Paris, France. He is
a member of several national and international medical societies,
including the American College of Rheumatology, and is former-President
(2011-2012) of OARSI (Osteoarthritis Research Society International).
He is Associate Editor of the Annals of the Rheumatic Diseases and on
the editorial boards of Nature Reviews in Rheumatology, Arthritis
Research and Therapy and Joint Bone Spine. Dr Berenbaum's basic
research interests include the role of inflammation in osteoarthritis
and the understanding of relationships between metabolic diseases and
osteoarthritis. His clinical research focuses on hand osteoarthritis
and on new targeted therapies for treating symptoms and structural
changes in osteoarthritis. Francis Berenbaum received his MD in
Rheumatology in 1993, followed by a PhD in 1995.
|
|
|
|
Virginia
Byers Kraus, M.D., Ph.D. |
|
|
|
Dr. Kraus is Professor of Medicine at Duke
University and a practicing Rheumatologist with 20 years experience in
Osteoarthritis research. She headed the NIHAMS/NIA OA Biomarker Network
from 2003 to 2006 and is now the co-PI with Dr. Linda Sandell, on the
U13 conference grant series of three Osteoarthritis Biomarker Global
Initiative Workshops. She also served as the Chair of the OARSI-FDA
Biomarkers Working Group. She directs the Biological Studies Core
Laboratory for the Duke Aging Center and the Biomarkers Core Laboratory
for the Duke Program Project Grant in Osteoarthritis. Dr. Kraus
supervises a laboratory devoted to translational research to advance
the understanding of the pathogenesis of osteoarthritis and to
contribute to definitive remittive therapies for the disease. She has a
special interest in strategies to reduce the incidence of
post-traumatic osteoarthritis. The work in the laboratory focuses on
the discovery and validation of novel in vitro and in vivo biochemical
and genetic biomarkers for early osteoarthritis detection, prediction
of progression, and monitoring of disease status and severity. In
addition she is President Elect and Executive Committee member of OARSI
to promote global research toward the prevention and treatment of
osteoarthritis.
|
|
|
David Hunter, M.D., Ph.D
|
| |
.Dr. David
Hunter is Professor of Medicine at University of Sydney and Consultant
Rheumatologist at Royal North Shore Hospital and North Sydney
Orthopedic and Sports Medicine Centre. Since receiving his Ph.D. in
2001 from the University of Sydney Dr. Hunter has gained world wide
recognition as one of the leading researchers in osteoarthritis. This
reputation arises from his significant contributions in the area of
clinical research in osteoarthritis. In his current work Dr. Hunter is
investigating a number of key elements in osteoarthritis including the
epidemiology of osteoarthritis, genetic epidemiology of osteoarthritis,
the role of biomarkers in understanding osteoarthritis
aetiopathogenesis, the application of imaging to better understand
structure and function with application to both epidemiologic research
and clinical trials, the application of novel therapies in disease
management and heath service system delivery of chronic disease
management. He is a board member of the International Osteoarthritis
Research Society and founded the Osteoarthritis Imaging Group. He is an
advisory editor for the premier rheumatology journal Arthritis and
Rheumatism, and an associate editor for Osteoarthritis and Cartilage,
Arthritis Care and Research, and BMC Musculoskeletal Disorders. He is a
member of the Australian College of Physicians, Australian Rheumatology
Association, American College of Rheumatology, Orthopaedic Research
Society and International Osteoarthritis Research Society.
|
|
|
Lee S. Simon, M.D., F.A.C.P.,
F.A.C.R.
|
| |
Dr.
Simon has been a
clinical Rheumatologist for 25 years and is a Principal in SDG LLC, a
consulting firm helping companies to create successful drug development
programs, and also serves as Head regulatory consultant to Leerink
Swann/Medacorp. Dr. Simaon has been the Division Director of Analgesic,
Anti-inflammatory and Ophthalmologic Drug Products (DAAODP), within the
Center
for Drug Evaluation and Research (CDER), FDA. He has served on and has
been the
Acting Chair of the Arthritis Advisory Committee of the DAAODP. He has
also
served on the advisory committees for the Division of Over the Counter
Drugs,
Center for Devices, and for the Division of Hematologic and
Gastroenterologic
Drug Products. He is a fellow of the American
College
of Physicians and the American College of
Rheumatology. Dr.
Simon has had extensive experience in
drug development, including drugs and other therapeutics used for pain,
anti-inflammatory effects, alteration of bone turnover, as well as
modifying
inflammatory disease states. He has served on the Board of Directors of
the American
College
of Rheumatology (ACR), served as
the Chair of Education for both the ACR and the National Arthritis
Foundation.
He was an Associate Professor of Medicine at Harvard
Medical
School,
an Associate Chief of Medicine, Beth
Israel
Deaconess
Medical
Center
(BIDMC), and Chair of Rehabilitation Services at the Deaconess
Hospital,
Harvard Medical School
before joining the
FDA.
|
|
|
|
| |
|
|
|
|
© TransPharma Medical™
Ltd. All Rights Reserved.
updated May 2008
|
|
